Valeant May Have Plunged Too Far Even in Worst Case, Mizuho Says
- Shares worth at least $100 even in `catastrophic scenarios'
- `The stock is no longer trading on fundamentals,' analyst says
Have Valeant's Shares Fallen Too Far?
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. has fallen too far.
In a worst-case scenario, the drugmaker’s shares are worth about 25 percent more than the $78.77 price where they closed Thursday, according to Irina Koffler, an analyst at Mizuho Securities. Even if the company’s chief executive officer steps down and Valeant is put up for sale, the company is probably worth at least $100 a share, she said.